The European Commission Has Approved AstraZeneca's Voydeya (Danicopan) As An Add-on To Ravulizumab Or Eculizumab For Paroxysmal Nocturnal Hemoglobinuria Patients Who Have Residual Hemolytic Anemia
欧盟委员会已批准阿斯利康的Voydeya（Danicopan）作为Ravulizumab或Eculizumab的附加组件，用于有残留溶血性贫血的阵发性夜间血红蛋白尿症患者